SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

• Status: Recruiting
• Trial end date: 2024-05-31

Summary

This research study is studying a drug as a possible treatment for diagnosis of AML, BPDCN and high-risk MDS.

The interventions involved in this study are:

• SL-401

• Azacitidine

• Venetoclax

• Phase: Phase 1

Details

• Lead Sponsor: Dana-Farber Cancer Institute
• Collaborator: Stemline Therapeutics, Inc.
• Treatments: Azacitidine; Venetoclax